Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group

Pediatr Blood Cancer. 2018 Jan;65(1):10.1002/pbc.26753. doi: 10.1002/pbc.26753. Epub 2017 Aug 12.

Abstract

Background: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL.

Procedure: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample.

Results: Fifty-eight (35.1%) cases showed only typical nodular with or without serpiginous histology (types A and B). The remainder showed mixtures of histologies. The numbers of patients with score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type C), 3 with T-cell-rich nodular pattern (type D), 55 (32.7%) with diffuse T-cell-rich (type E) pattern, and 2 (1.2%) with diffuse B-cell pattern (type F). Higher level of types C (P = 0.048) and D (P = 0.033) resulted in lower event-free survival (EFS). Cytoplasmic IgD was found in 65 of 130 tested (50%), did not significantly associate with EFS but positively correlated with types C and E histology (P < 0.0001) and negatively correlated with types A (P = 0.0003) and B (P = 0.006). Seventeen (10%) expressed CD30, with no adverse effect.

Conclusions: Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.

Keywords: Hodgkin; children; histology; lymphoma; pathology.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adolescent
  • B-Lymphocytes* / metabolism
  • B-Lymphocytes* / pathology
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Hodgkin Disease* / metabolism
  • Hodgkin Disease* / mortality
  • Hodgkin Disease* / pathology
  • Humans
  • Immunoglobulin D / biosynthesis*
  • Immunohistochemistry
  • Infant
  • Infant, Newborn
  • Ki-1 Antigen / biosynthesis*
  • Male
  • Survival Rate
  • T-Lymphocytes* / metabolism
  • T-Lymphocytes* / pathology

Substances

  • Immunoglobulin D
  • Ki-1 Antigen